Skip to main content
S 3582 109th Congress Senate

Preserve Access to Affordable Generics Act

Official title: A bill to prohibit brand name drug companies from compensating generic drug companies to delay the entry of a generic drug into the market.

Introduced: June 27, 2006 See on congress.gov
Commerce Drug industryGeneric drugsHealthIntellectual property
More subjectsShow fewer subjects
MarketingPatent infringementPharmaceutical researchScience, Technology, Communications
Sign in to write a letter Sign in to watch
This bill died when the 109th Congress ended
It never became law before the 109th Congress (2005–2006) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 3 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Jun 27, 2006
Read twice and referred to the Committee on Commerce, Science, and Transportation. (text of measure as introduced in Senate: CR S6578)
Jun 27, 2006
Sponsor introductory remarks on measure. (CR S6577-6578)
Jun 27, 2006
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action June 27, 2006

Read twice and referred to the Committee on Commerce, Science, and Transportation. (text of measure as introduced in Senate: CR S6578)

 Plain-English summary Congressional Research Service

Preserve Access to Affordable Generics Act - Amends the Federal Trade Commission Act to deem it to be an unfair method of competition affecting commerce for a person, in connection with the sale of a drug product, to be a party to any agreement resolving or settling a patent infringement claim in which: (1) an abbreviated new drug (generic) application filer receives anything of value; and (2) such filer agrees not to research, develop, manufacture, market, or sell the generic product for any period. Excludes a resolution or settlement that includes no more than the right to market the generic product prior to the expiration of the patent.

 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 2
All 2 Democratic 1 Republican 1
R
Grassley, Chuck
Iowa · Jun 27, 2006
 D
Schumer, Charles E.
New York · Jun 27, 2006
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3582: Preserve Access to Affordable Generics Act. 109th Congress. Open America. https://openamerica.io/bill/109-S-3582/
MLA
"S. 3582: Preserve Access to Affordable Generics Act." 109th Congress, 2026, Open America, https://openamerica.io/bill/109-S-3582/.
Bluebook (legal)
S. 3582, 109th Cong. (2026), https://openamerica.io/bill/109-S-3582/.
Markdown link
[S. 3582: Preserve Access to Affordable Generics Act](https://openamerica.io/bill/109-S-3582/)
Report a problem